Reading OGEN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OGEN free→Reading OGEN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OGEN free→QuarterlyIQ Insights · OGEN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
OTHER INFORMATION. On March 10, 2026, Oragenics, Inc. (the “Company”) issued a press release announcing that it had received final Human Research Ethics Committee (HREC) approval in Australia to commence the Company’s Phase IIa clinical trial evaluating the Company’s lead drug candidate, ONP-002, for the treatment of concussion and mild traumatic brain injury (mTBI). On March 11, 2026, the Company issued a press release announcing that the Company is exploring discussions with third parties r…
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. (e) Compensatory Arrangements of Certain Officers. Executive Officer Compensation . The Board of Directors (the “Board”) of Oragenics, Inc. (the “Company”), consistent with the previously disclosed compensation program, reviewed the base compensation of the Company’s Chief Executive Officer, Ms. Janet Huffman, and on December 11, 2025, the Board au…
Entry into a Material Definitive Agreement On October 16, 2025, the Company entered into a Settlement Agreement (the “ Settlement Agreement ”) with Ladenburg Thalmann & Co., Inc. (“ Ladenburg ”), pursuant to which the Company and Ladenburg agreed to settle all claims between the parties, including those arising under the Investment Banking Agreement between the parties dated December 7, 2022 (the “ IB Agreement ”). As previously reported, Ladenburg claimed it was due $2,500,000 in connection…
Notice of Delisting or Failure to Satisfy A Continued Listing Rule or Standard; Transfer of Listing. On October 20, 2025, Oragenics, Inc. (the “ Company ”) received a letter from the NYSE American informing the Company it has regained compliance with the stockholder’s equity requirements of the NYSE American continued listing standards. As such, it is expected that at the opening of trading on October 21, 2025, the below compliance (“.BC”) indicator will be removed and the Company will be rem…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 1, 2025, the board of directors (the “ Board ”) of Oragenics, Inc. (the “ Company ”) appointed Ms. Natasha Giordano to the Company’s Board. Ms. Giordano, since July 2, 2025, has served as the Board Chair for Incora Health and, since August 2024, has served on the Compensation Committee and on the Board of Directors of Afaxys Inc…
MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS. The matters described in
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. Public Offering On July 1, 2025, Oragenics, Inc. (the “Company”) entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Dawson James Securities Inc. (“ Dawson James ” or the “ Placement Agent ”) pursuant to which the Company engaged Dawson James as the placement agent for a registered public offering by the Company (the “ Offering ”) of an aggregate of (i) 660,000 shares of the Company’s newly designated Series H Convert…
Material Modification to the Rights of Security Holders. Reverse Stock Split To the extent required by
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. ( e) Compensatory Arrangements of Certain Officers. The information set forth in
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On May 2, 2025, the Board of Directors (the “Board”) of Oragenics, Inc. (the “Company”) appointed Janet Huffman, the Company’s Chief Financial Officer and Interim Chief Executive Officer, to serve as the Company’s Chief Executive Officer, in addition to continuing to serve as its Chief Financial Officer, and, in connection therewith, effective May 2, 2025, the Company entered into an Executive Employment Agreement with Ms. Huffman (the “Employment Ag…
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On January 16, 2025, the Board of Directors (the “Board”) of Oragenics, Inc. (the “Company”) appointed Ms. Janet Huffman, the Company’s Chief Financial Officer and Interim Principal Executive Officer, to also serve as the Company’s Interim Chief Executive Officer effective as of January 16, 2025, and in connection therewith, the Board of Directors determined that, effective January 16, 2025, Ms. Huffman’s employment agreement would be modified to (i)…
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. (a) Resignation of Director. On January 15, 2025, Mr. Bruce Cassidy resigned as director of the Company to pursue other opportunities. Mr. Cassidy’s resignation was not due to any disagreement with the Company on any matter related to its operations, policies or practices. ( e) Compensatory Arrangements of Certain Officers. The information set fort…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.